These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37137864)

  • 1. [Research progress on the correlation between changes in gut microbiota and sarcopenia in patients with cirrhosis].
    Jia SH; Zhang JK
    Zhonghua Gan Zang Bing Za Zhi; 2023 Mar; 31(3):332-336. PubMed ID: 37137864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota.
    Maslennikov R; Alieva A; Poluektova E; Zharikov Y; Suslov A; Letyagina Y; Vasileva E; Levshina A; Kozlov E; Ivashkin V
    World J Gastroenterol; 2023 Jul; 29(27):4236-4251. PubMed ID: 37545638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcopenia in Patients with Advanced Liver Disease.
    Ponziani FR; Gasbarrini A
    Curr Protein Pept Sci; 2018; 19(7):681-691. PubMed ID: 28462693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the gut-liver-muscle axis in cirrhotic patients with sarcopenia.
    Ponziani FR; Picca A; Marzetti E; Calvani R; Conta G; Del Chierico F; Capuani G; Faccia M; Fianchi F; Funaro B; Josè Coelho-Junior H; Petito V; Rinninella E; Paroni Sterbini F; Reddel S; Vernocchi P; Cristina Mele M; Miccheli A; Putignani L; Sanguinetti M; Pompili M; Gasbarrini A;
    Liver Int; 2021 Jun; 41(6):1320-1334. PubMed ID: 33713524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis.
    Nishikawa H; Enomoto H; Nishiguchi S; Iijima H
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32722100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nutritional support in cirrhotic patients with sarcopenia.
    Vasques J; Guerreiro CS; Sousa J; Pinto M; Cortez-Pinto H
    Clin Nutr ESPEN; 2019 Oct; 33():12-17. PubMed ID: 31451247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The critical role of gut microbiota dysbiosis in skeletal muscle wasting: a systematic review.
    Nikkhah A; Ejtahed HS; Ettehad Marvasti F; Taghavi M; Pakmehr A; Hajipour F; Larijani B
    J Appl Microbiol; 2023 Jan; 134(1):. PubMed ID: 36626794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress in the treatment of sarcopenia in patients with cirrhosis].
    Zhang JT; Kong M; Geng N; Lin N; Chen Y; Duan ZP
    Zhonghua Gan Zang Bing Za Zhi; 2023 Dec; 31(12):1340-1344. PubMed ID: 38253082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Protein Intake in Older Adults with Sarcopenia and Obesity: A Gut Microbiota Perspective.
    Prokopidis K; Cervo MM; Gandham A; Scott D
    Nutrients; 2020 Jul; 12(8):. PubMed ID: 32751533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the gut microbiota in hemodialysis patients with sarcopenia.
    Zhou Q; Zhang H; Yin L; Li G; Liang W; Chen G
    Int Urol Nephrol; 2022 Aug; 54(8):1899-1906. PubMed ID: 34845594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-Like Receptors Recognize Intestinal Microbes in Liver Cirrhosis.
    Fan Y; Li Y; Chu Y; Liu J; Cui L; Zhang D
    Front Immunol; 2021; 12():608498. PubMed ID: 33708204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
    Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
    Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiota and physical frailty through the mediation of sarcopenia.
    Casati M; Ferri E; Azzolino D; Cesari M; Arosio B
    Exp Gerontol; 2019 Sep; 124():110639. PubMed ID: 31226349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Mechanisms and Treatment of Sarcopenia in Liver Disease: A Review of Current Knowledge.
    Kamimura H; Sato T; Natsui K; Kobayashi T; Yoshida T; Kamimura K; Tsuchiya A; Murayama T; Yokoyama J; Kawai H; Takamura M; Terai S
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review.
    Gu X; Lu Q; Zhang C; Tang Z; Chu L
    Semin Liver Dis; 2021 Nov; 41(4):495-506. PubMed ID: 34261137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis.
    Shu W; Shanjian C; Jinpiao L; Qishui O
    Ann Hepatol; 2022; 27(2):100676. PubMed ID: 35093600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gut microbiota-bile acid axis: A potential therapeutic target for liver fibrosis.
    Zhang YL; Li ZJ; Gou HZ; Song XJ; Zhang L
    Front Cell Infect Microbiol; 2022; 12():945368. PubMed ID: 36189347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.